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Abstract
The feasibility and early toxicity of radiotherapy with carbogen breathing and nicotinamide was tested in 74 head and neck cancer 
patients, Forty patients with laryngeal and hypopharyngeal tumors were treated with an accelerated schedule combined with car­
bogen alone (16) or with carbogen and nicotinamide (24). Thirty-four patients with far advanced unresectable tumors of the oral 
cavity and oropharynx received conventional radiotherapy with carbogen [16] or with carbogen and nicotinamide (18), Some 
enhancement of skin reaction was observed with nicotinamide but this remained well within limits of tolerance. With the accelerated 
regimen there was increased severity of mucosal damage expressed as confluent mucositis in 95% of patients which required healing 
times of 3 -4  months in four patients. Eventually restoration of the mucosal lining was complete in all cases. Nausea and vomiting 
are the most frequent side effects of nicotinamide and were reported by 60% and 36% of the subjects, respectively. In 26% this 
was reason to discontinue drug intake. Severe renal dysfunction was associated with nicotinamide intake in two patients of this 
study and in one other patient who presented later. It is our conclusion that radiotherapy combined with carbogen and 
nicotinamide is a safe treatment with manageable side effects. We recommend not to give nicotinamide concomitantly with 
nephrotoxic medication or to patients who have impaired renal function. Preliminary tumor control rates are encouraging and clini­
cal testing will be continued.
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1. Introduction
It is well recognized that hypoxia is an important fac­
tor determining the radiation response o f squamous cell 
carcinomas. In man, the existence of hypoxia and its 
relationship to the outcome o f radiation therapy has 
been demonstrated in carcinomas o f the head and neck 
and uterine cervix [5,9,18,19]. Randomized clinical trials 
with hyperbaric oxygen and hypoxic cell radiosensitizers 
have shown significantly improved local control rates in 
carcinomas of the head and neck [7,8,21,22]. However, 
these approaches have not gained general acceptance. 
The side effects o f many radiosensitizers hamper their 
clinical use although some newer drugs are less toxic.
* Corresponding author,
Delivery of radiation in hyperbaric oxygen is a deman­
ding technique and often hypofractionation has been 
used, but this is currently not considered optimal be­
cause of reduced sparing o f late reacting normal tissues. 
Two mechanisms underlying tumor hypoxia are 
recognized. Chronic hypoxia results from the limited 
diffusion distance of oxygen in tissue [27], whereas acute 
or transient hypoxia is caused by local fluctuations in 
tumor blood perfusion [2,3]. Agents that modify tumor 
microcirculatory function may reduce acute hypoxia. 
The amide derivative of vitamin B3, nicotinamide, has 
recently received attention in this respect [11,16]. It was 
suggested that nicotinamide could further enhance the 
sensitizing effect of carbogen as a method to eliminate 
chronic hypoxia [24]. Polarographic studies have shown 
that carbogen (95% 0 2 + 5% C 0 2) breathing can
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increase the oxygen partial pressure and reduce chronic 
hypoxia in patients with head and neck tumors [20]. 
Relative to radiation treatment in air without the drug, 
enhancement ratios in the order of 1.8 have been obtain­
ed for treatment with carbogen and nicotinamide in 
mouse tumors [17].
Another important factor determining the radiation 
response of tumors is cellular repopulation. There is evi­
dence from clinical studies that patients with head and 
neck carcinomas may benefit from accelerated frac­
tionated irradiation to counteract repopulation o f  
tumor clonogens which occurs during the course o f  
treatment [1,26]. Results of randomized trials are 
expected soon.
Rojas et al. proposed the .strategy of combining accel­
erated radiotherapy with carbogen and nicotinamide 
(ARCON) to overcome both the compensating effect o f  
tumor repopulation and chronic and acute hypoxia [25]. 
This is a report on the feasibility and toxicity of this 
approach in patients with carcinomas of the head and 
neck.
2. Patients and methods
2.L Design o f the study
Two categories of patients were eligible for the study. 
One category includes patients with laryngeal (stage 
III—IV) and hypopharyngeal (stage II—IV) tumors 
receiving primary radiotherapy as larynx conserving 
treatment. The other category of patients had far ad­
vanced unresectabel tumors, mostly of the oral cavity 
and oropharynx and were referred for palliative 
radiotherapy. It was planned to first treat 15 patients 
with carbogen alone in each category. After this had 
been shown to be feasible and without severe direct
toxicity, nicotinamide was added. Since experience was 
previously obtained with an accelerated schedule in 
laryngeal cancers [13], it was decided to build on this 
experience and to add carbogen and nicotinamide as 
second and third steps, respectively. For the oral cavity 
and oropharyngeal tumors carbogen breathing and 
nicotinamide were added stepwise to a conventional 
radiation schedule. The patients with laryngeal and 
hypopharyngeal tumors were analyzed separately from 
those with oral cavity and oropharyngeal tumors 
because normal tissue effects as well as treatment out­
come are expected to be different in the two groups.
This work was approved by the local ethical com­
mittee.
2.2. Patients
Seventy-four consecutive patients were entered into 
the study over the period November 1992 until February 
1995. Inclusion criteria were: age over 18 years, WHO
performance status o f 0 -2 , no severe heart or lung 
disease, no severe liver or kidney function disturbances, 
no severe stridor, no distant metastases, and written in­
formed consent. Another six patients were eligible but 
refused participation. Thirteen patients were ineligible 
for the following reasons: poor performance status (9), 
severe cardiac and pulmonary disease (4), claustro­
phobia (1), and Rendu-Osler-Weber disease with severe 
anemia (1). The patients entered in the study had a mean
age o f 57 years (range 2 7 -8 2  years). There were 60 men 
and 14 women. All patients had squamous cell car­
cinomas except one with a mucoepidermoid carcinoma 
of the larynx. Three patients had two concurrent 
primary tumors in the head and neck area. Two other 
patients had recurrent disease after surgical treatment. 
Characteristics o f the patients, their tumors, and the 
treatment are shown in Table 1.
2,5. Radiotherapy
The primary tumor and bilateral neck nodes were 
irradiated through lateral opposed photon beams (4 and
6 MV). The inferior border was generally placed just 
superior to the arytenoids for oral cavity and 
oropharyngeal tumors. For tumors o f larynx and 
hypopharynx the inferior border was placed just above 
the shoulders. After 30 -40  Gy, an off-cord reduction 
was made and the posterior cervical chains were treated
with lateral appositional electron beams. The mid- and 
lower-neck nodes were treated with an anterior photon 
field. In some cases a posterior field was added to sup­
plement the dose in the posterior midcervical chains. 
The boost dose was delivered through reduced lateral or 
oblique opposed portals combined, when necessary, 
with an electron beam to boost nodal areas overlying the 
spinal cord or larynx. Conventional radiotherapy was 
given in fractions o f 2 Gy, five times a week. Total dose 
was 68 Gy for gross disease and 44 Gy for the areas 
treated electively. Overall treatment time was 46 -48  
days. With the accelerated schedule, the dose per frac­
tion remained 2 Gy but treatment time was reduced by 
10 days by giving two fractions per day during the last 
one and a half weeks o f treatment. Intervals between 
fractions was at least 6 h.
Sensitization o f laryngeal cartilage has been reported 
after radiotherapy in hyperbaric oxygen [8], A 10% 
reduction of total dose in a subsequent study o f hyper­
baric oxygen reduced the laryngeal complications to a 
level seen with treatment in air [7]. Since a similar effect 
might be expected from normobaric carbogen with 
nicotinamide, the maximal permissible dose to the lar­
ynx was reduced from 70 to 64 Gy and, as a conse­
quence, tumor dose for primaries o f the larynx and 
hypopharynx did not exceed this limit. Involved nodes 
received 68 Gy. Because a decrease in tolerance o f the 
rat spinal cord o f  —20% was observed when radiation
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Table 1
Number of patients according to treatment and site of primary disease and clinical stage (UICC 1992 staging system)
Treatment
Conv RT + Carb Conv RT + Acc RT + Carb Acc RT 4 *
Carb + Nie Carb + Nie
No. patients 16 18 16 24
Mean age (range) 55 (41-76) 53 (27-73) 60 (39-82) 60 (41-78)
Stage
T* --- l b — ---
Ti 2 --- --- %
t 2 --- --- 7 1
t 3 5a 8 C 8 13
t 4 8 9 I 4
No 3 3 6 U
N, 2 4 7 5
--- --- --- --
N2b 1 5 2 1
Njo 8 4 1 7
N 3 1 2 --- --
Not classatile 1 --- --- ---
»
Site of primary
Oral cavity
Oral tongue 1 3 --- --
Floor of mouth --- 5b --- --
Oropharynx
Soft palate 1 1 --- --
Tonsillar fossa 5 5C --- ---
Base of tongue 7* 3 --- --
Pharyngeal wall 1 --- --- --
Maxillary sinus --- 1 -— ---------
Auditory canal 1 --- --- --
Larynx
Supraglottic --- 1 0 1 1
Glottic --- --- 3 5
Hypopharynx
Pyriform sinus --- --- 2 6
Postcricoid --- --- 1 2
No. patients receiving 8 8 —— 2
chemotherapy
aOne patient with synchronous second primary of soft palate (T2). 
bOne patient with synchronous second primary of pyriform sinus (T2). 
cOne patient with synchronous second primary of vallecula (Tl).
was combined with carbogen and nicotinamide [6], total 
dose to the spinal cord was not higher than 40 Gy. Dose 
specification was according to Report 29 of the ICRU 
[12].
2,4, Carbogen breathing
Scuba-diving equipment was used for carbogen deliv­
ery, This system transports the gas from the reservoir to 
the patient by way of a two-step pressure reduction. The 
second stage of the breathing regulator is connected to 
a disposable anesthetic face mask which is incorporated 
in the immobilizing cast. Details o f this breathing system 
have been described earlier [14]. Carbogen breathing
commenced 4 min before start of irradiation of the 
macroscopic tumor localizations and was continued 
throughout the treatment. During the 4-min pre­
irradiation breathing time fields were set up and unin­
volved supraclavicular nodes were treated. Pre­
irradiation breathing time and total breathing time were 
recorded.
2.5. Nicotinamide
Nicotinamide, dissolved in fruit juice,' was ad­
ministered orally 1.5 h before irradiations. On days 
when two fractions were given, only one dose of 
nicotinamide was taken before the first treatment. In­
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itially the daily dose was 6 g. After April 1994, when 
more pharmacokinetic data became available, this was 
changed to a weight-adjusted dose of 80 mg/kg with a 
maximum of 6 g.
2.6, Monitoring during treatment
Blood pressure and heart rate were measured on the 
first 5 treatment days just before and after irradiations. 
This was discontinued after the first 20 patients because 
no changes had been observed.
Blood samples were drawn once a week for blood cell 
counting and hemoglobin concentration measurement.
When hemoglobin concentrations fell below 7 mmol/1 
this was corrected by blood transfusions. Initially, 
serum liver enzymes, sodium, potassium, urea, and 
creatinine were determined before and in the last week
of the treatment. Later this was also done weekly during 
the course of irradiation.
Weekly assessment of acute mucosal and skin reac­
tions started in the first week of treatment and con­
tinued during treatment and thereafter until the lesions 
started to heal. Patients were then seen once every 2 or 
3 weeks until healing was complete. Reactions of 
mucosa and skin and dysphagia were scored as shown 
in Table 2. Since 1987 this scoring system is applied 
routinely to all patients receiving radiotherapy to the 
head and neck area in our institute.
2.7, Additional treatment
Eighteen patients received chemotherapy prior to 
radiation treatment. In most cases this consisted of cis-
Table 2
Scores for mucosal and  skin reactions
Acute reactions Score
Mucosa
normal 0
slight redness I
severe redness 2
spotted mucositis 3
confluent mucositis <  50% o f  irradiated surface 4
confluent mucositis >  50% o f  irradiated surface 5
Dysphagia
no complaints 0
complaints, no m edication 1
medication needed 2
liquid feeding 3
tube feeding 4
Skin
normal 0
slight redness 1
severe redness 2
dry desquam ation 3
moist desquam ation <  50% of irradiated surface 4
moist desquam ation >  50% of irradiated surface 5
platin weekly for one to six courses. One patient was 
treated with three courses o f methotrexate, bleomycin, 
vinblastine, and cisplatin. All these patients had far 
advanced unresectable tumors. After radiotherapy two 
patients underwent neck dissections for residual nodal 
disease
2.8. S tatistics
Fisher’s exact probability test was used to test the 
significance o f differences in acute toxicity scores 
between groups. Average durations o f mucosal and skin 
reactions were compared by the Mest.
3. Results
5. L Carbogen breathing
Measurements of blood pressure and heart rate before 
and after carbogen breathing were discontinued after no 
apparent changes were observed in the first 20 patients. 
Six of the 74 patients were unable to continue carbogen 
breathing throughout the entire course o f irradiation. 
Two patients underwent a tracheostomy, one because of 
edema and the other because o f  tumor progression; the 
other four patients experienced sensations o f  suffoca­
tion, sometimes accompanied by extreme hyperventila­
tion. Pre-irradiation breathing time was less than 4 min 
in 1.2% (25/2123) o f radiation sessions but never less 
than 3 min. It was longer than 6 min in 5.8%, usually 
due to delays in the treatment set up. Total breathing 
time was more than 15 min 6.7% o f times, mostly when 
complicated techniques were used to limit the dose to 
the spinal cord.
5.2. Nicotinamide
The most common side effects from nicotinamide 
were nausea and vomiting, reported, respectively, by 25
(60%) and 15 (36%) of the 42 patients taking the drug. 
Ten patients were nauseous after the first dose of 
nicotinamide. Often these complaints were unresponsive 
to anti-emetics including ondansetron. Eleven patients 
(26%) discontinued the intake o f nicotinamide due to 
severe nausea and vomiting. One patient was under 
treatment when adjustments o f nicotinamide dose were 
made from 6 g to individual weight-corrected doses. In 
this patient nausea disappeared when the dose was 
reduced from 6 to 4 g (80 mg/kg). Apart from this one 
patient we observed no differences in side effects be­
tween patients taking 6 g and those taking 80 mg/kg. 
Five patients reported flushing 0 .5 -2  h after ingestion. 
One patient showed signs o f depression which disap­
peared within a few days after nicotinamide was discon­
tinued. One patient refused to continue nicotinamide
intake because o f the bad taste. N o serum liver enzyme
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disturbances related to nicotinamide were observed. 
Twelve patients had isolated elevation of 7 -glutamyl 
transpeptidase (7 -GT), mostly already before start of 
treatment, which was ascribed to alcohol abuse.
Two patients developed severe renal dysfunction 
following nicotinamide administration. Patient 1 receiv­
ed daily doses o f 6 g and patient 2 received 5.5 g. Both 
patients complained o f nausea and vomiting and patient 
2 also had severe diarrhea. This was reason to discon­
tinue the drug in both patients. Both were admitted to 
the hospital a few days later with dehydration and renal 
dysfunction. Patient 1 was known to suffer from type I 
diabetes mellitus and hypertension and concomitant 
medication consisted o f  insulin, lisinopril (angiotensin 
converting enzyme-ACE-inhibitor), bisoprolol (selective 
/3-blocker), carbasalatcalcium and ondansetron. Patient
2 was on metocl oprami de, oxazepam and an antacid. 
Prior to the start of radiotherapy he received six weekly 
cycles of cisplatin, 70 mg/m2. Maximum recorded 
serum levels of creatinine were 2290 ¿unol/1 in patient 1 
and 1096 ¿imol/1 in patient 2. Renal function recovered 
with rehydration and bicarbonate administration in 
both patients. In addition, both patients developed
thrombopenia of uncertain etiology. Patient 1 also had 
moderate and transient elevation o f liver enzymes 2 
weeks after discontinuation o f nicotinamide. She fully 
recovered and could resume radiotherapy. Patient 2 had 
an episode of ventricular tachycardia, possibly as a 
result of electrolyte disturbances. He had a large 
unresectable tumor and progression o f disease already 
under chemotherapy and it was decided to stop further 
radiation treatment because o f the very poor prognosis.
3.3. Radiotherapy
Three patients did not complete the planned radiation 
treatment. One patient died from a massive bleeding in 
the tumor, one patient developed distant metastases 
during loco-regional treatment and the third patient as 
mentioned above had rapid tumor progression, renal 
complications and deterioration o f general condition. 
Total treatment duration exceeded 48 days in four o f the 
34 patients treated according to the conventional sched­
ule. Reasons were: renal complications (6 days); 
tracheostomy (1 day); machine breakdown (1 day); holi­
day, not compensated for (1 day). Of the 40 patients
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treated by the accelerated schedule only one surpassed 
the maximum allowed treatment time of 38 days with a 
single day because of a holiday that was not compen­
sated for.
3.4. Early reactions o f  mucosa and skin
Scores for acute radiation reactions during and after 
treatment are shown in Figs. 1 and 2. Only the highest 
scores are shown because scores 1 and 2 have limited 
clinical significance and are nearly always followed by 
more severe reactions. For the group of patients treated 
with conventional radiotherapy and carbogen (C) con­
fluent mucositis occurred in 81% of the cases, and with 
addition o f nicotinamide (N) this was 83%. Average 
duration was 3.5 (C) and 5.1 (C+N) weeks {p = 0.08, t- 
test). The accelerated schedule caused confluent 
mucositis in all but two cases (95%) with an average 
duration o f 6.3 (C) and 6.7 (C+N) weeks. Prolonged 
duration o f confluent mucositis, i.e., persisting more 
than 6 weeks after the end of treatment, was observed
1
in four patients after the accelerated regimen. In all 
cases healing was complete within 3 -4  months after 
treatment. Tube feeding was needed in 29% of patients
with oral cavity and oropharynx tumors and in 26% o f
patients with laryngeal and hypopharyngeal tumors 
with no significant differences between patients receiv­
ing carbogen alone and those receiving carbogen and 
nicotinamide. Objective and functional mucosal reac­
tions were not more severe for patients who received 
chemotherapy prior to irradiation (data not shown).
Addition o f nicotinamide appeared to somewhat 
increase skin reactions. The conventional schedule with 
carbogen caused moist desquamation in four of 16 pa­
tients (25%) and in 10 o f 18 patients (56%) who received 
also nicotinamide (p = 0.06, Fisher’s exact test), With 
the accelerated schedule this was nine o f  16 (56%; C) and 
15 of 23 (65%; C+N). Generally the skin healed rapidly 
within 3 weeks except in one case in which it required
7 weeks. This patient was in the conventional schedule 
with carbogen and nicotinamide.
3.5 . Locoregional tum or control
All 39 patients with tumors o f larynx and 
hypopharynx who finished the planned course o f irradi­
ation had complete disappearance o f locoregional 
tumor at 6 weeks after the end of treatment. Actuarial
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locoregional control at one year was 86%, with 21 pa­
tients being in follow-up at least a year after treatment. 
Thirty-two patients with oral cavity and oropharynx 
tumors completed treatment, o f whom 20 (63%) had 
complete regression o f  disease at 6 weeks. The one-year 
actuarial locoregional control rate for this group was 
41%, with 23 patients in follow-up one year or more 
after treatment.
4, Discussion
Carbogen breathing by the method described 
previously [14] appears to be feasible and well tolerated, 
even by patients with large tumors in the upper aero- 
digestive tract. Only four o f 74 patients were unable to 
cope with the procedure because they experienced sensa­
tions o f suffocation, in some cases with hyperventilation 
which is caused by the carbon dioxide component of the 
gas. Polarographic 0 2 measurements in metastatic 
lymph nodes from head and neck carcinomas showed 
that breathing time before optimal oxygenation was 4 
min or less in 19 o f 20 patients [20]. It was also 
demonstrated that tumor p 0 2 starts to decline after 
12-18 min o f carbogen breathing [4], Thus, irradiations 
are best delivered between 4 and 15 min after the start 
of carbogen breathing when tumor oxygenation is at its 
peak level. This was accomplished in 92% of our radia­
tion sessions.
Reported side effects o f nicotinamide are: nausea, 
vomiting, flushing, facial erythema, headache, fatigue, 
cutaneous reactions, and rare events o f liver toxicity 
[29]. Doses of nicotinamide o f  up to 6 g daily were 
described as reasonably safe and associated with a low
incidence o f side effects. In our experience, with doses of 
6 g/day or 80 mg/kg/day, nausea and vomiting occurred 
frequently and necessitated discontinuation o f the drug 
in 26%) of patients. Gastrointestinal symptoms were also
reported in other clinical pilot studies: three of six pa­
tients with head and neck cancer [30], two of six patients 
with breast cancer [23], and in two o f 16 patients with 
malignant gliomas [28]. The mechanism by which these 
symptoms are produced is not clear: there may be a sys­
temic effect or topical irritation o f the gastrointestinal 
mucosa. In the latter case, an alternative route of admin­
istration might reduce these unpleasant side effects. Se­
vere renal dysfunction was associated with nicotinamide 
intake in two patients. When this article was being 
finalized a third patient presented with this complica­
tion, also after previous treatment with cisplatin. Thus, 
two patients received previous (cisplatin) and one con­
comitant (ACE-inhibitor, carbasalatcalcium) nephro­
toxic medication. This, in combination with decreased 
renal flow due to hypovolemia as a result o f nicotin- 
amide-induced vomiting and decreased oral fluid intake, 
may well be the cause o f rapidly developing renal fail­
ure. Any direct renal toxicity from nicotinamide can,
however, not be excluded. It was shown that the drug
inhibits renal clearance of 51CrEDTA and l25I-iodo- 
hippurate in mice [10]. These effects were dose-related 
and evident at doses from 400 mg/kg upwards which is 
considerably higher than the doses clinically applied. 
Only one previous case of renal toxicity in man has been 
reported by Zackrisson et al. [30]. This patient received 
two daily doses of 6 and 3 g. He had a known cardio­
myopathy and was on treatment with an ACE-inhibitor 
as was one of our patients. The patient had nausea and 
vomiting and developed hypotension with elevation of 
serum creatinine and liver enzymes. Plasma concentra­
tions of nicotinamide and its metabolites suggested that 
renal elimination was impaired. Possibly in patients with 
compromised renal function (nephrotoxic medication, 
hypovolemia) nicotinamide accumulates in the plasma 
to a level at which it can aggravate renal dysfunction 
and may lead to severe renal failure.
Unlike our experience with glioma patients [28], we 
did not observe nicotinamide-related hepatic toxicity in 
this category of head and neck cancer patients. One of
the patients with renal complications had moderate 
elevation of liver enzymes but this was unlikely to be re­
lated to nicotinamide intake because it started 2 weeks 
after discontinuation o f the drug. Apparently it was the 
combination with anti-epileptics and steroids that in­
duced liver toxicity in the glioma patients,
Nowadays with the availability of megavoltage equip­
ment the incidence of severe skin reactions is low. We 
previously reported an 8% rate of moist desquamation 
for conventional radiotherapy with total doses of 68-70  
Gy [13]. In this study we observed rates of 25% (C) and 
56% (C+N). This increased skin reaction is not unex­
pected as enhancement ratios of 1.3-1.5 were estimated 
for rodent skin [17]. With the accelerated schedule alone 
50% of patients develop moist desquamation [13]. When 
carbogen and nicotinamide are added there is only a 
small further increase to 56% (C) and 65% (C+N) which 
is not statistically significant. Apart from one case, skin 
lesions healed rapidly. The early reacting tissue of great­
er clinical significance is the mucosal membrane. With 
the conventional schedule, 81% (C) and 83% (C+N) of 
patients in this study developed confluent mucositis of 
the oral cavity and oropharynx. This corresponds to the 
78% rate that we observed when these areas were treated 
with radiotherapy alone [15]. Acceleration of treatment 
causes confluent mucositis in up to 90% of patients with 
laryngeal cancer, with complete healing within 6 weeks 
after completion of treatment in all cases [13]. In this 
study confluent mucositis occurred in 95% of patients (C 
and C+N). However, four patients had healing times of 
up to 4 months. A possible increase of severity of 
mucosal damage by addition of carbogen and 
nicotinamide may well be expressed as delayed recovery. 
We believe that the acute radiation toxicity as observed 
with the current regimen is acceptable but we do not ad­
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vocate further intensification of treatment as this might 
lead to non-healing lesions and consequential late 
effects.
In conclusion it is our opinion that radiotherapy 
combined with carbogen and nicotinamide is a safe 
treatment with manageable side effects. No expensive 
additional equipment is needed and it requires hardly 
any extra machine time. Certain precautions should be 
taken, however, especially with regard to nicotinamide 
administration. We recommend that nicotinamide 
should not be given to patients presenting with elevated 
serum creatinine levels and it should not be given con­
comitantly with nephrotoxic medication. During treat­
ment, renal function should be monitored at least once 
a week and twice weekly in patients at risk (e.g., those 
who were treated previously with cisplatin). Adequate 
oral intake is demanded. When serum creatinine rises 
above normal levels, nicotinamide should be discon­
tinued immediately and proper hydration must be
secured, if necessary by intravenous infusion.
Possibly, side effects of nicotinamide can be limited 
when individual dose adjustments are made or when an 
alternative route of administration is used. Currently we 
are monitoring nicotinamide plasma levels in our pa­
tients to assess whether proper levels are obtained when 
treatment is given on a day to day routine basis and also 
to investigate if these are related to the observed side 
effects.
Preliminary tumor control rates are promising and 
the approach offers potentials for larynx preservation. 
In the category of far advanced tumors proposed for 
palliative treatment, complete regressions were achieved 
and sustained in a significant proportion of the patients. 
We expect to increase the effectiveness of the treatment 
for this particular category with introduction o f the
accelerated schedule. Our experience with ARCON so 
far is encouraging and we will proceed with further clini­
cal testing.
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